



Lobramil (RMP-7, Cereport®)

At the Clinical Center referred to as lobramil.

How Given: Intravenously (by vein)

Drug Action: The “blood brain barrier” acts as a gate, preventing many medications from getting into the brain. Lobramil temporarily opens this gate, allowing certain chemotherapy medications into the brain.

Side Effects:

1. A drop in blood pressure can occur with the start of the infusion and last up to 1 hour after the infusion ends. This can cause dizziness and lightheadedness.
2. The following symptoms can occur with the start of the infusion and usually stop by the end of the infusion:
 - facial flushing, feeling hot
 - severe headache
 - stomach ache
 - nausea and severe vomiting
 - urgent need to pass urine

Special Instructions:

1. Tell your nurse immediately if you have any dizziness, lightheadedness, facial flushing, a warm feeling, headache, stomach ache, nausea, or vomiting.



This information is prepared specifically for patients participating in clinical research at the Warren Grant Magnuson Clinical Center at the National Institutes of Health and is not necessarily applicable to individuals who are patients elsewhere. If you have questions about the information presented here, talk to a member of your healthcare team.

Living with Cancer Chemotherapy Series
January, 1983; draft September, 1998
National Institutes of Health, CC
Nursing Department

Questions about the Clinical Center? OCCC@cc.nih.gov